Ruxolitinib
A JAK1/JAK2 inhibitor used to treat myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease, and as a topical cream for atopic dermatitis and vitiligo. It reduces the overactive inflammatory signaling pathway that drives these conditions.
Moleküler Ağırlık
306,4000 g/mol
LogP
2,10
TPSA
83,20 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
Etki Mekanizması
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
2D Yapı
Cite this structure
Embed this structure
SMILES
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
InChI
InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1
Molecular Formula
C17H18N6
HBD / HBA
1 / 4
Döndürülebilir Bağlar
4
Ağır Atomlar
23
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A JAK1/JAK2 inhibitor used to treat myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease, and as a topical cream for atopic dermatitis and vitiligo. It reduces the overactive inflammatory signaling pathway that drives these conditions.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Ruxolitinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1789941. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 25126798. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ruxolitinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ruxolitinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ruxolitinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ruxolitinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ruxolitinib"></drugfyi-drug>